DOI: 10.1097/01.hpc.0000137966.55044.37

,  

,  

PMID: 18340162

Issn Print: 1535-282X

Publication Date: 2004/09/01


Print

Type 2 Diabetes and the Metabolic Syndrome: National Cholesterol Education Program Guidelines and Supporting Evidence

Steven M. Haffner

    loading  Checking for direct PDF access through Ovid

Excerpt

Type 2 diabetes affects approximately 15 million Americans.1 The prevalence of this disorder is increasing, rising from 7.3% in 2000 to 7.9% in 2001, an increase of 8.2%.2 Coronary heart disease (CHD) is a major burden in patients with type 2 diabetes and is the leading cause of death among these patients.2 Because patients with diabetes are at high risk of death as a result of cardiovascular causes, a more intensive lipid-lowering strategy is necessary.
There is growing evidence that the risk for CHD starts long before the onset of clinical diabetes. Patients with higher baseline levels of total and low-density lipoprotein cholesterol (LDL-C) and lower high-density lipoprotein cholesterol (HDL-C)3 and impaired glucose tolerance4 are more likely to develop diabetes. Therefore, close attention should be paid to these risk factors.
Metabolic syndrome, comprising a constellation of major risk factors, also increases the risk of CHD and has been recognized by the most recent National Cholesterol Education Program (NCEP) guidelines as a secondary target of lipid-lowering therapy.

Related Topics

    loading  Loading Related Articles